CJCatherine B. Jensen

Catherine B. Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine B. Jensen has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Guidelines: Nonclinical Drivers of Surgical Recommendations in Low-Risk Thyroid Cancer

    by Steven Xie, Catherine B. Jensen, Elizabeth M. Bacon, Sarah E. Bradley, Mary E. Byrnes, J.D. Thomas, Susan C. Pitt, Michael A. Rubyan

  • Open Access

    Communication of Cost in Thyroidectomy: A Mixed‐Methods Analysis of Financial Toxicity

    by Derek D. Kao, Emily V. Crowley, Catherine B. Jensen, Elizabeth M. Bacon, Sarah E. Bradley, J. Denard Thomas, Susan C. Pitt

    Objective: To assess cost information provided to patients undergoing thyroidectomy. Study Design: Explanatory sequential mixed‐methods study. Setting: Single academic medical center. Methods: Adults who underwent thyroidectomy between 1/2021 and 1/2024 completed a survey about financial toxicity. Purposive sampling identified survey respondents for semi‐structured interviews to explore experiences related to cost communication. Qualitative data were thematically analyzed. Results: Of 167 survey respondents, most were female (77.8%), white (83.8%), and underwent total thyroidectomy (65.3%). Nearly one‐third experienced moderate to severe financial toxicity. Forty‐one percent felt “not at all” informed about costs, while 20% sought preoperative cost information, most commonly from insurers (82.4%). Education was significantly associated with feeling cost‐informed, while lowest‐ and highest‐income, younger, and female patients trended toward greater cost‐seeking behavior. Thirty‐five respondents were invited for an interview; 20 consented. Almost all participants recalled no cost discussion with their care team. Several felt like they “had to” have surgery, regardless of cost, and many were surprised by copays, missed work, and medication costs. Some wished they had received estimates or information about financial resources. Participants identified insurers as a source for cost information but received vague communication regarding coverage. A few stated that while better cost information would not have changed their treatment decision, it would have better prepared them for the financial impact. Conclusion: Patients undergoing thyroidectomy appear to be insufficiently informed of costs before surgery. Improved cost communication by care teams and hospital systems could improve preparedness and mitigate financial toxicity, as reliance on insurers alone appears inadequate.

  • Open Access

    Disparities in utilization of high-volume thyroid surgeons for Graves disease: a statewide analysis

    by Steven Xie, Catherine B Jensen, Aayushi Sinha, Elizabeth M Bacon, Lauren N Krumeich, Hunter J Underwood, David T Hughes, Paul G Gauger, Hari Nathan, Michael A Rubyan, et al.

    Context: For patients with Graves disease undergoing surgery, the American Thyroid Association guidelines recommend referral to a high-volume thyroid surgeon (HVTS). However, factors limiting patient utilization of an HVTS are poorly understood. Objective: This study aimed to identify factors associated with utilization of an HVTS for patients with Graves. Methods: This retrospective cohort study analyzed adults with Graves who underwent thyroidectomy from January 2015 to December 2022 in a statewide claims registry. Surgeons were categorized as HV (>25 thyroidectomies/year) or low-volume (LVTS; ≤25 thyroidectomies/year). Logistic regression evaluated patient demographics, travel distance to treating HVTS hospital and closest endocrinologist, household income, area deprivation index, and education. Results: Among 764 patients treated by 130 surgeons, 17 HVTSs performed the majority (60.4%) of thyroidectomies. Most patients were female (84.3%) and White (51.0%). Patients treated by an HVTS traveled 16.8 miles farther (P < .001). On multivariable analysis, distance traveled to the treating hospital (odds ratio [OR] 1.01; 95% CI, 1.003-1.014) and education of a patient's home zip code (OR 0.87; 95% CI, 0.83-0.91) were significant predicators of using an HVTS. Proximity to an endocrinologist was not associated with utilization (P = .45). Surgery by an HVTS was associated with lower rates of hypocalcemia (18.2% vs 24.8%; P = .03) and cardiac events (10.4% vs 17.2%; P = .008). Conclusion: Just more than half of patients with Graves disease received guideline-concordant surgical care by an HVTS. Enhancing patient knowledge and awareness of the benefits of HVTS care and solving transportation barriers may improve Graves patients’ use of HVTS and outcomes.

  • Open Access

    A missed opportunity to discuss treatment costs? A qualitative analysis of preoperative conversations about thyroid cancer treatment

    by Emily V. Crowley, Catherine B. Jensen, Elizabeth M. Bacon, Benjamin C. James, Susan C. Pitt

  • Statewide episode spending variation of thyroidectomy for lower-risk thyroid cancer

    by Catherine B. Jensen, Steven Xie, Aayushi Sinha, Elizabeth M. Bacon, Hunter J. Underwood, Hari Nathan, Susan C. Pitt

  • Open Access

    Mixed-Methods Assessment of Thyroid Cancer-Related Fear and State Anxiety in Patients with Benign Thyroid Nodules

    by Ailish Dougherty, Nicolas Robinson, Melis Ozkan, Ibrahim Khan, Kayla Roche, Emily Evans, Catherine B. Jensen, Brandy Sinco, Kyle J. Bushaw, Megan C. Saucke, et al.

  • Thyroid Cancer-Specific Worry in the United States: A Survey

    by Emily E. Evans, Catherine B. Jensen, Alexander S. Chiu, Ines Hoxha, Megan C. Saucke, Susan C. Pitt


  • Harnessing the Power of Physician Word Choice in Thyroid Cancer Treatment Decision-Making

    by Catherine B. Jensen, Kathryn Flaharty, Hunter J. Underwood, Michael A. Rubyan, Brian J. Zikmund-Fisher, Susan C. Pitt


  • Open Access

    The Fear Factor: How Cancer Recurrence Shapes Treatment Choices About Thyroid Cancer

    by Catherine B. Jensen, Susan C. Pitt


  • The Effect of a Surgeon Communication Strategy on Treatment Preference for Thyroid Cancer: A Randomized Trial

    by Catherine B. Jensen, Brandy Sinco, Megan C. Saucke, Kyle J. Bushaw, Alexis G. Antunez, Corrine I. Voils, Susan C. Pitt

    Background: Cancer diagnosis causes emotional distress, which can influence patients’ treatment choice. This study aimed to investigate the effect of increased emotionally supportive surgeon communication in a virtual setting on treatment preference for thyroid cancer. Design: This randomized trial (NCT05132478), conducted from November 2021 to February 2023, enrolled adults with ≤4-cm thyroid nodules not requiring surgery. Participants were randomized 1:1 to watch a virtual clinic visit depicting a patient–surgeon treatment discussion for low-risk thyroid cancer. Control and intervention videos were identical except for added emotionally supportive communication in the intervention. The primary outcome was treatment preference for total thyroidectomy or lobectomy. Secondary outcomes were perceived physician empathy, physician trust, decisional confidence, and disease-specific knowledge. An intention-to-treat analysis was performed using conditional regression to account for stratification by sex. Qualitative content analysis evaluated participants’ open-ended responses about treatment choice and surgeon communication. Results: Of 208 eligible patients, 118 (56.7%) participated. Participants were 85.6% female and 88.1% White. Overall, 89.0% ( n = 105) of participants preferred lobectomy, which was similar between the intervention and control groups (90.0% v. 87.9%, respectively, P = 0.72). Compared with control, participants who viewed the consultation with enhanced communication perceived higher levels of physician empathy (34.5 ± 5.8 v. 25.9 ± 9.1, P < 0.001) and reported increased trust in the physician (12.0 ± 2.6 v. 10.4 ± 3.1, P < 0.001). The groups were similar in decisional confidence (7.6 ± 2.1 v. 7.7 ± 1.9, P = 0.74) and disease-specific knowledge. Prominent qualitative themes among participants choosing thyroid lobectomy included desire to avoid daily thyroid hormone ( n = 53) and concerns about surgical complications ( n = 25). Conclusions: In this randomized controlled study, a significant proportion of participants preferred thyroid lobectomy if diagnosed with low-risk thyroid cancer. Participants perceived increased empathy when provided even in the virtual setting, which was associated with increased trust in the physician. Highlights: In this single-site, randomized controlled trial, enhanced emotionally supportive surgeon communication had no effect on hypothetical treatment preference for low-risk thyroid cancer. Participants who experienced enhanced emotionally supportive surgeon communication perceived higher physician empathy and reported greater trust in the physician. The incorporation of empathetic communication during surgical consultation for low-risk thyroid cancer promotes patient trust and perception of empathy.